Halozyme Therapeutics, Inc.

HALONASDAQHealthcare● Active

$71.10

$-0.43(-0.60%)

Market Cap$8.4B

P/E Ratio—

52W High$82.22

52W Low$51.06

Avg Volume1.6M

Open$71.59

Beta0.87

Cash on Hand Financials Revenue

Halozyme Therapeutics, Inc. (HALO) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

HALO · cash on hand · updated Dec 31, 2025

Core cash position

as of Dec 31, 2025

Cash & Short-Term Investments (CCE + ST Investments)

$142.8M▼ -76.0% vs prior year

FY · as of Dec 31, 2025 · Reported in USD

Cash & Cash Equiv. (CCE)

$133.8M

cashAndCashEquivalents

Short-Term Investments

$9.0M

shortTermInvestments

YoY Change vs Prior Year

-76.0%

vs prior fiscal year

Latest Quarter

$318.6M

Q1 2026

Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2025

Net cash vs debt

Cash vs Debt · Balance Sheet Health

Cash & ST Investments$142.8MCash on Hand

Total Debt$2.14BTotal Debt

Net Cash / Net Debt−$2.00BNet Debt Position

Cash vs Debt Ratio

Cash 6%Halozyme Therapeutics, Inc. cash as % of market cap: 1.69%% · MCap $8BDebt 94%

Halozyme Therapeutics, Inc. carries a net debt position of $2.00B. Total debt ($2.14B) exceeds cash on hand ($142.8M). Halozyme Therapeutics, Inc. cash vs debt ratio: 6% cash / 94% debt.

Net Cash = Cash & ST Investments − Total Debt$142.8M − $2.14B = −$2.00B

Cash on hand history

annual cash on hand trend · Cash & Short-Term Investments

YoY Increase

YoY Decrease

Latest Year

HALO annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

HALO cash & short-term investments history

DatePeriodCash & ST InvestmentsYoY Change

Dec 31, 2025LatestFY$142.8M-76.0%

Dec 31, 2024FY$596.1M+77.4%

Dec 31, 2023FY$336.0M-7.4%

Dec 31, 2022FY$362.8M-51.0%

Dec 31, 2021FY$740.9M+101.3%

HALO cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

HALO vs peers · cash on hand

#CompanyCash & ST Inv.Market CapCash/MCapRelative

UnitedHealth Group Incorporated

Eli Lilly and Company

Halozyme Therapeutics, Inc.YOU

HALO

$142.8M$8B1.7%

Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Halozyme Therapeutics, Inc. (HALO) cash on hand as of December 31, 2025 is $142.8M, comprising $133.8M in cash and cash equivalents (CCE) plus $9.0M in short-term investments — reported as Halozyme Therapeutics, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Halozyme Therapeutics, Inc. cash reserves or cash position.

Halozyme Therapeutics, Inc. annual cash on hand history shows decreased -76.0% in 2025: decreased -76.0% in 2025. Halozyme Therapeutics, Inc. cash reserves in 2025 reflect the company's capital allocation strategy.

Halozyme Therapeutics, Inc. carries total debt of $2.14B against cash of $142.8M, resulting in a net debt position of -$2.00B. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.

Financial statements Free cash flow Net income Revenue Market cap P/E ratio Earnings Price history

Frequently asked questions

HALO cash on hand · 5 questions

As of December 31, 2025, Halozyme Therapeutics, Inc. (HALO) has $142,820,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $133,820,000 in cash and cash equivalents (CCE) plus $9,000,000 in short-term investments. Latest quarter (March 31, 2026): $318,622,000. Data sourced from the annual 10-K filing via FMP.

HALO cash on handHALO cash reservesHALO cash 2025how much cash does HALO have

▸ Source: FMP /balance-sheet-statement · US GAAP · Halozyme Therapeutics, Inc. · Halozyme Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2025